Scinai Immunotherapeutics (SCNI) Net Income towards Common Stockholders (2014 - 2026)

Scinai Immunotherapeutics (SCNI) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 57.33% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$6.2 million (up 53.88% YoY), and the FY2025 full-year result was -$38.3 million, down 18.32% from the prior year.
• Net Income towards Common Stockholders eased to -$2.5 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $3.6 million in Q2 2023 to a low of -$19.8 million in Q4 2022.
• A 5-year average of -$2.3 million and a median of -$1.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 327.21% in 2023 and plunged 120999900.0% in 2024, its largest moves.
• Tracing SCNI's Net Income towards Common Stockholders over 5 years: stood at -$19.8 million in 2022, then jumped by 90.24% to -$1.9 million in 2023, then sank by 88.3% to -$3.6 million in 2024, then surged by 39.63% to -$2.2 million in 2025, then fell by 12.39% to -$2.5 million in 2026.
• Business Quant data shows SCNI's Net Income towards Common Stockholders at -$2.5 million in Q1 2026, -$2.2 million in Q2 2025, and -$1.6 million in Q1 2025.